Agile Therapeutics Announces Issuance of Patent for Twirla(R) Patch Design
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Agile Therapeutics (AGRX) Issued Twirla-Related U.S. Patent
June 12, 2015 7:43 AM EDTAgile Therapeutics (Nasdaq: AGRX) announced that the U.S. Patent and Trademark Office issued US Patent 9,050,358 on June 9, 2015. The newly-issued patent includes claims directed to the peripheral adhesive system used in the Company's lead product candidate Twirla (ethinyl estradiol and levonorgestrel transdermal system... More
